Clinical trial
Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in…
NCT00049764 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00049764 |
|---|---|
| Title | Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis |
| Official title | Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sepsis |
| Intervention type | Drug |
| Interventions | Drotrecogin alfa (activated), Placebo |
| Enrollment | 474 |
| Start date | Nov 1, 2002 |
| Completion | Apr 1, 2005 |
| First posted | Nov 14, 2002 |
| Last update posted | Nov 20, 2007 |
| Countries | Australia, Chile, France, Germany, Italy, Mexico, Poland, Slovakia, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: